Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia

Thromb Haemost 2004; 91(01): 196-197
DOI: 10.1055/s-0037-1614256

Case Report

Schattauer GmbH

Pierre Fontana

¹Françoise Boehlen, Victor Janer, Gürkan Kaya, Marc Righini

,

Alexandre Bodmer

¹Françoise Boehlen, Victor Janer, Gürkan Kaya, Marc Righini

,

Yves Gruel

¹Françoise Boehlen, Victor Janer, Gürkan Kaya, Marc Righini

References
1 Wutschert R, Piletta P, Bounameaux H. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Drug Saf 1999; 20: 515-25.
2 Pouplard C, Amiral J, Borg JY. et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700-6.
3 Pouplard C, Amiral J, Borg JY. et al. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on crossreactivity with danaparoid sodium. Br J Haematol 1997; 99: 273-80.
4 Gruel Y, Pouplard C, Nguyen P. et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121: 786-92.
5 Balestra B, Quadri P, Dermarmels FBiasiutti. et al. Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites. Eur J Haematol 1994; 53: 61-3.
6 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-92.